Skip to main content
SpringerLink
Log in

Targeting Tumours with Radiolabeled Antibodies

  • Chapter
Targeted Radionuclide Tumor Therapy

Summary

The introduction of radiolabelled antibodies targeting the lymphocyte antigen CD20 in certain hematologic malignancies received positive attention and is now accepted as a treatment modality. Treating solid tumours with radiolabelled antibodies has, so far, not been met with the same appreciation and such therapy for the large groups of malignancies like colorectal, breast, prostate, ovarian, lung cancer and brain tumours still require improvements in order to gain acceptance. In this chapter limitations, possibilities and future directions to improve therapy with radiolabelled antibodies are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Goldenberg DM: Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 2002; 43:693-713.

    PubMed  CAS  Google Scholar 

  2. Boswell CA, Brechbiel MW: Development of radioimmunotherapeutic and diagnostic antibodies: An inside-out view. Nucl Med Biol 2007; 34:757-778.

    PubMed  CAS  Google Scholar 

  3. Goldenberg DM, Sharkey RM: Advances in cancer therapy with radiolabeled monoclonal antibodies. Q J Nucl Med Mol Imaging 2006; 50:248-264.

    PubMed  CAS  Google Scholar 

  4. Imam SK: Status of radioimmunotherapy in the new millennium. Cancer Biother Radiopharm 2001; 16:237-256.

    PubMed  CAS  Google Scholar 

  5. Oriuchi N, Higuchi T, Hanaoka H, Iida Y, Endo K: Current status of cancer therapy with radiolabeled monoclonal antibody. Ann Nucl Med 2005; 19:355-365.

    PubMed  CAS  Google Scholar 

  6. Goldenberg DM: The role of radiolabeled antibodies in the treatment of non-hodgkin’s lymphoma: The coming of age of radioimmunotherapy. Crit Rev Oncol Hematol 2001; 39:195-201.

    PubMed  CAS  Google Scholar 

  7. Silverman DH, Delpassand ES, Torabi F, Goy A, McLaughlin P, Murray JL: Radiolabeled antibody therapy in non-hodgkins lymphoma: Radiation protection, isotope comparisons and quality of life issues. Cancer Treat Rev 2004; 30:165-172.

    PubMed  CAS  Google Scholar 

  8. Russeva MG, Adams GP: Radioimmunotherapy with engineered antibodies. Expert Opin Biol Ther 2004; 4:217-231.

    PubMed  CAS  Google Scholar 

  9. Bethge WA, Sandmaier BM: Targeted cancer therapy and immunosuppression using radiolabeled monoclonal antibodies. Semin Oncol 2004; 31:68-82.

    PubMed  CAS  Google Scholar 

  10. Koppe MJ, Postema EJ, Aarts F, Oyen WJ, Bleichrodt RP, Boerman OC: Antibody-guided radiation therapy of cancer. Cancer Metastasis Rev 2005; 24:539-567.

    PubMed  CAS  Google Scholar 

  11. Vose JM: Bexxar: Novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin’s lymphoma. Oncologist 2004; 9:160-172.

    PubMed  CAS  Google Scholar 

  12. Gordon LI, Witzig T, Molina A, Czuczman M, Emmanouilides C, Joyce R, Vo K, Theuer C, Pohlman B, Bartlett N, Wiseman G, Darif M, White C: Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated b-cell lymphoma. Clin Lymphoma 2004; 5:98-101.

    PubMed  CAS  Google Scholar 

  13. Milenic DE, Brady ED, Brechbiel MW: Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov 2004; 3:488-499.

    PubMed  CAS  Google Scholar 

  14. Walsh G: Biopharmaceutical benchmarks 2006. Nat Biotechnol 2006; 24:769-776.

    PubMed  CAS  Google Scholar 

  15. DeNardo GL, Kennel SJ, Siegel JA, Denardo SJ: Radiometals as payloads for radioimmunotherapy for lymphoma. Clin Lymphoma 2004; 5(Suppl 1):S5-S10.

    PubMed  CAS  Google Scholar 

  16. Press OW: Radioimmunotherapy for non-Hodgkin’s lymphomas: A historical perspective. Semin Oncol 2003; 30:10-21.

    PubMed  CAS  Google Scholar 

  17. Macklis RM, Pohlman B: Radioimmunotherapy for non-Hodgkin’s lymphoma: A review for radiation oncologists. Int J Radiat Oncol Biol Phys 2006; 66:833-841.

    PubMed  Google Scholar 

  18. Linden O, Hindorf C, Cavallin-Stahl E, Wegener WA, Goldenberg DM, Horne H, Ohlsson T, Stenberg L, Strand SE, Tennvall J: Dose-fractionated radioimmunotherapy in non-hodgkin’s lymphoma using dota-conjugated, 90y-radiolabeled, humanized anti-cd22 monoclonal antibody, epratuzumab. Clin Cancer Res 2005; 11:5215-5222.

    PubMed  CAS  Google Scholar 

  19. DeNardo GL, Kukis DL, Shen S, DeNardo DA, Meares CF, DeNardo SJ: 67cu-versus 131ilabeled lym-1 antibody: Comparative pharmacokinetics and dosimetry in patients with nonHodgkin’s lymphoma. Clin Cancer Res 1999; 5:533-541.

    PubMed  CAS  Google Scholar 

  20. Beatty JD, Williams LE, Yamauchi D, Morton BA, Hill LR, Beatty BG, Paxton RJ, Merchant B, Shively JE: Presurgical imaging with indium-labeled anti-carcinoembryonic antigen for colon cancer staging. Cancer Res 1990; 50:922s-926s.

    PubMed  CAS  Google Scholar 

  21. Bischof-Delaloye A, Delaloye B, Buchegger F, Gilgien W, Studer A, Curchod S, Givel JC, Mosimann F, Pettavel J, Mach JP: Clinical value of immunoscintigraphy in colorectal carcinoma patients: A prospective study. J Nucl Med 1989; 30:1646-1656.

    PubMed  CAS  Google Scholar 

  22. Blumenthal RD, Sharkey RM, Kashi R, Goldenberg DM: Comparison of therapeutic efficacy and host toxicity of two different 131i-labelled antibodies and their fragments in the gw-39 colonic cancer xenograft model. Int J Cancer 1989; 44:292-300.

    PubMed  CAS  Google Scholar 

  23. Liersch T, Meller J, Kulle B, Behr TM, Markus P, Langer C, Ghadimi BM, Wegener WA, Kovacs J, Horak ID, Becker H, Goldenberg DM: Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131i-labetuzumab after salvage resection of colorectal metastases in the liver: Five-year safety and efficacy results. J Clin Oncol 2005; 23:6763-6770.

    PubMed  CAS  Google Scholar 

  24. Wong JY, Chu DZ, Williams LE, Yamauchi DM, Ikle DN, Kwok CS, Liu A, Wilczynski S, Colcher D, Yazaki PJ, Shively JE, Wu AM, Raubitschek AA: Pilot trial evaluating an 123i-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (ct84.66 minibody) in patients with colorectal cancer. Clin Cancer Res 2004; 10:5014-5021.

    PubMed  CAS  Google Scholar 

  25. Wong JY, Shibata S, Williams LE, Kwok CS, Liu A, Chu DZ, Yamauchi DM, Wilczynski S, Ikle DN, Wu AM, Yazaki PJ, Shively JE, Doroshow JH, Raubitschek AA: A phase I trial of 90y-anti-carcinoembryonic antigen chimeric t84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res 2003; 9:5842-5852.

    PubMed  CAS  Google Scholar 

  26. Chong G, Lee FT, Hopkins W, Tebbutt N, Cebon JS, Mountain AJ, Chappell B, Papenfuss A, Schleyer P, Paul U, Murphy R, Wirth V, Smyth FE, Potasz N, Poon A, Davis ID, Saunder T, O’Keefe G J, Burgess AW, Hoffman EW, Old LJ, Scott AM: Phase I trial of 131i-hua33 in patients with advanced colorectal carcinoma. Clin Cancer Res 2005; 11:4818-4826.

    PubMed  CAS  Google Scholar 

  27. Scott AM, Lee FT, Jones R, Hopkins W, MacGregor D, Cebon JS, Hannah A, Chong G, Paul U, Papenfuss A, Rigopoulos A, Sturrock S, Murphy R, Wirth V, Murone C, Smyth FE, Knight S, Welt S, Ritter G, Richards E, Nice EC, Burgess AW, Old LJ: A phase I trial of humanized monoclonal antibody a33 in patients with colorectal carcinoma: Biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin Cancer Res 2005; 11:4810-4817.

    PubMed  CAS  Google Scholar 

  28. Buchsbaum D, Khazaeli MB, Liu T, Bright S, Richardson K, Jones M, Meredith R: Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131i-labeled monoclonal antibody cc49. Cancer Res 1995; 55:5881s-5887s.

    PubMed  CAS  Google Scholar 

  29. Tempero M, Leichner P, Baranowska-Kortylewicz J, Harrison K, Augustine S, Schlom J, Anderson J, Wisecarver J, Colcher D: High-dose therapy with 90yttrium-labeled monoclonal antibody cc49: A phase I trial. Clin Cancer Res 2000; 6:3095-3102.

    PubMed  CAS  Google Scholar 

  30. DeNardo SJ, Kramer EL, O’Donnell RT, Richman CM, Salako QA, Shen S, Noz M, Glenn SD, Ceriani RL, DeNardo GL: Radioimmunotherapy for breast cancer using indium-111/ yttrium-90 bre-3: Results of a phase I clinical trial. J Nucl Med 1997; 38:1180-1185.

    PubMed  CAS  Google Scholar 

  31. DeNardo SJ, Kukis DL, Miers LA, Winthrop MD, Kroger LA, Salako Q, Shen S, Lamborn KR, Gumerlock PH, Meares CF, DeNardo GL: Yttrium-90-dota-peptide-chimeric l6 radioimmunoconjugate: Efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts. J Nucl Med 1998; 39:842-849.

    PubMed  CAS  Google Scholar 

  32. Schrier DM, Stemmer SM, Johnson T, Kasliwal R, Lear J, Matthes S, Taffs S, Dufton C, Glenn SD, Butchko G, et al.: High-dose 90y mx-diethylenetriaminepentaacetic acid (dtpa)bre-3 and autologous hematopoietic stem cell support (ahscs) for the treatment of advanced breast cancer: A phase I trial. Cancer Res 1995; 55:5921s-5924s.

    PubMed  CAS  Google Scholar 

  33. Behr TM, Sharkey RM, Juweid ME, Dunn RM, Vagg RC, Ying Z, Zhang CH, Swayne LC, Vardi Y, Siegel JA, Goldenberg DM: Phase I/II clinical radioimmunotherapy with an iodine131-labeled anti-carcinoembryonic antigen murine monoclonal antibody igg. J Nucl Med 1997; 38:858-870.

    PubMed  CAS  Google Scholar 

  34. Ebeling FG, Stieber P, Untch M, Nagel D, Konecny GE, Schmitt UM, Fateh-Moghadam A, Seidel D: Serum cea and ca 15-3 as prognostic factors in primary breast cancer. Br J Cancer 2002; 86:1217-1222.

    PubMed  CAS  Google Scholar 

  35. Burke PA, DeNardo SJ, Miers LA, Kukis DL, DeNardo GL: Combined modality radioimmunotherapy. Promise and peril. Cancer 2002; 94:1320-1331.

    PubMed  CAS  Google Scholar 

  36. Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL: Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 2002; 62:4263-4272.

    PubMed  CAS  Google Scholar 

  37. DeNardo SJ, Kukis DL, Kroger LA, O’Donnell RT, Lamborn KR, Miers LA, DeNardo DG, Meares CF, DeNardo GL: Synergy of taxol and radioimmunotherapy with yttrium-90-labeled chimeric l6 antibody: Efficacy and toxicity in breast cancer xenografts. Proc Natl Acad Sci USA 1997; 94:4000-4004.

    PubMed  CAS  Google Scholar 

  38. Bander NH: Technology insight: Monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol 2006; 3:216-225.

    PubMed  CAS  Google Scholar 

  39. Raj GV, Partin AW, Polascik TJ: Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer 2002; 94:987-996.

    PubMed  Google Scholar 

  40. Meredith RF, Bueschen AJ, Khazaeli MB, Plott WE, Grizzle WE, Wheeler RH, Schlom J, Russell CD, Liu T, LoBuglio AF: Treatment of metastatic prostate carcinoma with radiolabeled antibody cc49. J Nucl Med 1994; 35:1017-1022.

    PubMed  CAS  Google Scholar 

  41. Vallabhajosula S, Goldsmith SJ, Kostakoglu L, Milowsky MI, Nanus DM, Bander NH: Radioimmunotherapy of prostate cancer using 90y- and 177lu-labeled j591 monoclonal antibodies: Effect of multiple treatments on myelotoxicity. Clin Cancer Res 2005; 11:7195s-7200s.

    PubMed  CAS  Google Scholar 

  42. O’Donnell RT, DeNardo SJ, Miers LA, Lamborn KR, Kukis DL, DeNardo GL, Meyers FJ: Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-dota-peptide-chl6. Prostate 2002; 50:27-37.

    PubMed  Google Scholar 

  43. Epenetos AA, Hird V, Lambert H, Mason P, Coulter C: Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. Int J Gynecol Cancer 2000; 10:44-46.

    PubMed  Google Scholar 

  44. Buijs WC, Tibben JG, Boerman OC, Molthoff CF, Massuger LF, Koenders EB, Schijf CP, Siegel JA, Corstens FH: Dosimetric analysis of chimeric monoclonal antibody cmov18 igg in ovarian carcinoma patients after intraperitoneal and intravenous administration. Eur J Nucl Med 1998; 25:1552-1561.

    PubMed  CAS  Google Scholar 

  45. Buist MR, Molthoff CF, Kenemans P, Meijer CJ: Distribution of ov-tl 3 and mov18 in normal and malignant ovarian tissue. J Clin Pathol 1995; 48:631-636.

    PubMed  CAS  Google Scholar 

  46. Coliva A, Zacchetti A, Luison E, Tomassetti A, Bongarzone I, Seregni E, Bombardieri E, Martin F, Giussani A, Figini M, Canevari S: 90y labeling of monoclonal antibody mov18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas. Cancer Immunol Immunother 2005; 54:1200-1213.

    PubMed  CAS  Google Scholar 

  47. Nicodemus CF, Berek JS: Monoclonal antibody therapy of ovarian cancer. Expert Rev Anticancer Ther 2005; 5:87-96.

    PubMed  CAS  Google Scholar 

  48. Breitz HB, Weiden PL, Beaumier PL, Axworthy DB, Seiler C, Su FM, Graves S, Bryan K, Reno JM: Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90y-dota-biotin. J Nucl Med 2000; 41:131-140.

    PubMed  CAS  Google Scholar 

  49. Machac J, Krynyckyi B, Kim C: Peptide and antibody imaging in lung cancer. Semin Nucl Med 2002; 32:276-292.

    PubMed  Google Scholar 

  50. Forero A, Meredith RF, Khazaeli MB, Shen S, Grizzle WE, Carey D, Busby E, LoBuglio AF, Robert F: Phase I study of 90y-cc49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: Effect of chelating agents and paclitaxel co-administration. Cancer Biother Radiopharm 2005; 20:467-478.

    PubMed  CAS  Google Scholar 

  51. Arista A, Sturiale C, Riva P, Tison V, Frattarelli M, Moscatelli G, Franceschi G, Spinelli A: Intralesional administration of i-131 labelled monoclonal antibodies in the treatment of malignant gliomas. Acta Neurochir (Wien) 1995; 135:159-162.

    CAS  Google Scholar 

  52. Bigner DD, Brown M, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Bigner SH, Zhao XG, Wikstrand CJ, Pegram CN, et al.: Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131i-radiolabeled monoclonal antibodies anti-tenascin 81c6 and anti-chondroitin proteoglycan sulfate me1-14 f (ab’)2-a preliminary report. J Neurooncol 1995; 24:109-122.

    PubMed  CAS  Google Scholar 

  53. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, 2nd, Cokgor I, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Regalado LV, Sampson JH, Shafman TD, Wikstrand CJ, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD: Phase II trial of murine (131)i-labeled antitenascin monoclonal antibody 81c6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 2002; 20:1389-1397.

    PubMed  CAS  Google Scholar 

  54. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, 2nd, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Gururangan S, Badruddoja M, Dowell JM, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD: Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81c6 for patients with recurrent primary and metastatic malignant brain tumors: Phase II study results. J Clin Oncol 2006; 24:115-122.

    PubMed  CAS  Google Scholar 

  55. Quang TS, Brady LW: Radioimmunotherapy as a novel treatment regimen: 125i-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int J Radiat Oncol Biol Phys 2004; 58:972-975.

    PubMed  CAS  Google Scholar 

  56. Grana C, Chinol M, Robertson C, Mazzetta C, Bartolomei M, De Cicco C, Fiorenza M, Gatti M, Caliceti P, Paganelli G: Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: A pilot study. Br J Cancer 2002; 86:207-212.

    PubMed  CAS  Google Scholar 

  57. Paganelli G, Bartolomei M, Ferrari M, Cremonesi M, Broggi G, Maira G, Sturiale C, Grana C, Prisco G, Gatti M, Caliceti P, Chinol M: Pre-targeted locoregional radioimmunotherapy with 90y-biotin in glioma patients: Phase I study and preliminary therapeutic results. Cancer Biother Radiopharm 2001; 16:227-235.

    PubMed  CAS  Google Scholar 

  58. Rossi Norrlund R, Ullen A, Sandstrom P, Holback D, Johansson L, Stigbrand T, Hietala SO, Riklund Ahlstrom K: Dosimetry of fractionated experimental radioimmunotargeting with idiotypic and anti-idiotypic anticytokeratin antibodies. Cancer 1997; 80:2681-2688.

    PubMed  CAS  Google Scholar 

  59. Stigbrand T, Ullen A, Sandstrom P, Mirzaie-Joniani H, Sundstrom B, Nillson B, Arlestig L, Norrlund RR, Ahlstrom KR, Hietala S: Twenty years with monoclonal antibodies: State of the art-where do we go? Acta Oncol 1996; 35:259-265.

    PubMed  CAS  Google Scholar 

  60. Radford IR, Murphy TK, Radley JM, Ellis SL: Radiation response of mouse lymphoid and myeloid cell lines. Part II. Apoptotic death is shown by all lines examined. Int J Radiat Biol 1994; 65:217-227.

    PubMed  CAS  Google Scholar 

  61. Abend M: Reasons to reconsider the significance of apoptosis for cancer therapy. Int J Radiat Biol 2003;79:927-941.

    PubMed  CAS  Google Scholar 

  62. Eriksson D, Joniani HM, Sheikholvaezin A, Lofroth PO, Johansson L, Riklund Ahlstrom K, Stigbrand T: Combined low dose radio- and radioimmunotherapy of experimental hela hep 2 tumours. Eur J Nucl Med Mol Imaging 2003; 30:895-906.

    PubMed  CAS  Google Scholar 

  63. Eriksson D, Lofroth PO, Johansson L, Riklund KA, Stigbrand T: Cell cycle disturbances and mitotic catastrophes in hela hep2 cells following 2.5 to 10 Gy of ionizing radiation. Clin Cancer Res 2007; 13:5501s-5508s.

    PubMed  CAS  Google Scholar 

  64. Koral KF, Kaminski MS, Wahl RL: Correlation of tumor radiation-absorbed dose with response is easier to find in previously untreated patients. J Nucl Med 2003; 44:1541-1543; author reply 1543.

    PubMed  Google Scholar 

  65. Sgouros G, Squeri S, Ballangrud AM, Kolbert KS, Teitcher JB, Panageas KS, Finn RD, Divgi CR, Larson SM, Zelenetz AD: Patient-specific, 3-dimensional dosimetry in non-Hodgkin’s lymphoma patients treated with 131i-anti-b1 antibody: Assessment of tumor dose-response. J Nucl Med 2003; 44:260-268.

    PubMed  CAS  Google Scholar 

  66. Sharkey RM, Brenner A, Burton J, Hajjar G, Toder SP, Alavi A, Matthies A, Tsai DE, Schuster SJ, Stadtmauer EA, Czuczman MS, Lamonica D, Kraeber-Bodere F, Mahe B, Chatal JF, Rogatko A, Mardirrosian G, Goldenberg DM: Radioimmunotherapy of non-Hodgkin’s lymphoma with 90y-dota humanized anti-cd22 igg (90y-epratuzumab): Do tumor targeting and dosimetry predict therapeutic response? J Nucl Med 2003; 44:2000-2018.

    PubMed  CAS  Google Scholar 

  67. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-Lopez AJ, Multani P, White CA: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed b-cell non-Hodgkin’s lymphoma. J Clin Oncol 2002; 20:2453-2463.

    PubMed  CAS  Google Scholar 

  68. Gordon LI, Molina A, Witzig T, Emmanouilides C, Raubtischek A, Darif M, Schilder RJ, Wiseman G, White CA: Durable responses after ibritumomab tiuxetan radioimmunotherapy for cd20 + b-cell lymphoma: Long-term follow-up of a phase I/II study. Blood 2004; 103:4429-4431.

    PubMed  CAS  Google Scholar 

  69. Davis TA, Kaminski MS, Leonard JP, Hsu FJ, Wilkinson M, Zelenetz A, Wahl RL, Kroll S, Coleman M, Goris M, Levy R, Knox SJ: The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res 2004; 10:7792-7798.

    PubMed  CAS  Google Scholar 

  70. Mone AP, Huang P, Pelicano H, Cheney CM, Green JM, Tso JY, Johnson AJ, Jefferson S, Lin TS, Byrd JC: Hu1d10 induces apoptosis concurrent with activation of the akt survival pathway in human chronic lymphocytic leukemia cells. Blood 2004; 103:1846-1854.

    PubMed  CAS  Google Scholar 

  71. Leonard JP, Coleman M, Ketas JC, Chadburn A, Ely S, Furman RR, Wegener WA, Hansen HJ, Ziccardi H, Eschenberg M, Gayko U, Cesano A, Goldenberg DM: Phase I/II trial of epratuzumab (humanized anti-cd22 antibody) in indolent non-Hodgkin’s lymphoma. J Clin Oncol 2003; 21:3051-3059.

    PubMed  CAS  Google Scholar 

  72. Dechant M, Bruenke J, Valerius T: Hla class II antibodies in the treatment of hematologic malignancies. Semin Oncol 2003; 30:465-475.

    PubMed  CAS  Google Scholar 

  73. Liu C, DeNardo G, Tobin E, DeNardo S: Antilymphoma effects of anti-hla-dr and cd20 monoclonal antibodies (lym-1 and rituximab) on human lymphoma cells. Cancer Biother Radiopharm 2004; 19:545-561.

    PubMed  CAS  Google Scholar 

  74. Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, Regan D, Kison P, Fisher S, Kroll S, Wahl RL: 131i-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005; 352:441-449.

    PubMed  CAS  Google Scholar 

  75. Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Gaynor ER, Rivkin SE, Fisher RI: A phase II trial of chop chemotherapy followed by tositumomab/iodine i 131 tositumomab for previously untreated follicular non-hodgkin lymphoma: Southwest oncology group protocol s9911. Blood 2003; 102:1606-1612.

    PubMed  CAS  Google Scholar 

  76. Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, Regan D, Fisher S, Gutierrez J, Kroll S, Stagg R, Tidmarsh G, Wahl RL: Radioimmunotherapy with iodine (131)i tositumomab for relapsed or refractory b-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96:1259-1266.

    PubMed  CAS  Google Scholar 

  77. Gopal AK, Gooley TA, Maloney DG, Petersdorf SH, Eary JF, Rajendran JG, Bush SA, Durack LD, Golden J, Martin PJ, Matthews DC, Appelbaum FR, Bernstein ID, Press OW: High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: A multivariable cohort analysis. Blood 2003; 102:2351-2357.

    PubMed  CAS  Google Scholar 

  78. Jain RK: Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990; 50:814s-819s.

    PubMed  CAS  Google Scholar 

  79. Sheikholvaezin A, Eriksson D, Ahlstrom KR, Johansson L, Stigbrand T: Tumor radioimmunolocalization in nude mice by mono- and divalent- single-chain fv antiplacental alkaline phosphatase antibodies. Cancer Biother Radiopharm 2007; 22:64-72.

    PubMed  CAS  Google Scholar 

  80. Sheikholvaezin A, Eriksson D, Riklund K, Stigbrand T: Construction and purification of a covalently linked divalent tandem single-chain fv antibody against placental alkaline phosphatase. Hybridoma (Larchmt) 2006; 25:255-263.

    CAS  Google Scholar 

  81. Sheikholvaezin A, Sandstrom P, Eriksson D, Norgren N, Riklund K, Stigbrand T: Optimizing the generation of recombinant single-chain antibodies against placental alkaline phosphatase. Hybridoma (Larchmt) 2006; 25:181-192.

    CAS  Google Scholar 

  82. Rydh A, Riklund-Ahlstrom K, Widmark A, Bergh A, Johansson L, Tavelin B, Nilsson S, Stigbrand T, Damber JE, Hietala SO: Radioimmunotherapy of du-145 tumours in nude micea pilot study with e4, a novel monoclonal antibody against prostate cancer. Acta Oncol 1999; 38:1075-1079.

    PubMed  CAS  Google Scholar 

  83. Rossi Norrlund R, Ullen A, Sandstrom P, Holback D, Johansson L, Stigbrand T, Hietala SO, Ahlstrom KR: Experimental radioimmunotargeting combining nonlabeled, iodine-125-labeled, and anti-idiotypic anticytokeratin monoclonal antibodies: A dosimetric evaluation. Cancer 1997; 80:2689-2698.

    PubMed  CAS  Google Scholar 

  84. Behr TM, Sharkey RM, Juweid ME, Blumenthal RD, Dunn RM, Griffiths GL, Bair HJ, Wolf FG, Becker WS, Goldenberg DM: Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res 1995; 55:3825-3834.

    PubMed  CAS  Google Scholar 

  85. Behr TM, Sharkey RM, Sgouros G, Blumenthal RD, Dunn RM, Kolbert K, Griffiths GL, Siegel JA, Becker WS, Goldenberg DM: Overcoming the nephrotoxicity of radiometallabeled immunoconjugates: Improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry. Cancer 1997; 80:2591-2610.

    PubMed  CAS  Google Scholar 

  86. Jamar F, Barone R, Mathieu I, Walrand S, Labar D, Carlier P, de Camps J, Schran H, Chen T, Smith MC, Bouterfa H, Valkema R, Krenning EP, Kvols LK, Pauwels S: 86y-dota0)d-phe1-tyr3-octreotide (smt487) - a phase I clinical study: Pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 2003; 30:510-518.

    PubMed  CAS  Google Scholar 

  87. Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca P, Caracciolo M, Macke HR, Chinol M, Paganelli G: Receptor-mediated radionuclide therapy with 90y-dotatoc in association with amino acid infusion: A phase I study. Eur J Nucl Med Mol Imaging 2003; 30:207-216.

    PubMed  CAS  Google Scholar 

  88. Moll S, Nickeleit V, Mueller-Brand J, Brunner FP, Maecke HR, Mihatsch MJ: A new cause of renal thrombotic microangiopathy: Yttrium 90-dotatoc internal radiotherapy. Am J Kidney Dis 2001; 37:847-851.

    PubMed  CAS  Google Scholar 

  89. Cybulla M, Weiner SM, Otte A: End-stage renal disease after treatment with 90y-dotatoc. Eur J Nucl Med 2001; 28:1552-1554.

    PubMed  CAS  Google Scholar 

  90. van Eerd JE, Vegt E, Wetzels JF, Russel FG, Masereeuw R, Corstens FH, Oyen WJ, Boerman OC: Gelatin-based plasma expander effectively reduces renal uptake of 111in-octreotide in mice and rats. J Nucl Med 2006; 47:528-533.

    PubMed  Google Scholar 

  91. Vegt E, Wetzels JF, Russel FG, Masereeuw R, Boerman OC, van Eerd JE, Corstens FH, Oyen WJ: Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. J Nucl Med 2006; 47:432-436.

    PubMed  CAS  Google Scholar 

  92. Jaggi JS, Seshan SV, McDevitt MR, Sgouros G, Hyjek E, Scheinberg DA: Mitigation of radiation nephropathy after internal alpha-particle irradiation of kidneys. Int J Radiat Oncol Biol Phys 2006; 64:1503-1512.

    PubMed  Google Scholar 

  93. Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, Kvols LK, Krenning EP, Jamar F, Pauwels S: Patient-specific dosimetry in predicting renal toxicity with (90)y-dotatoc: Relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 2005; 46 Suppl 1:99-106.

    Google Scholar 

  94. Nilsson R, Lindgren L, Lilliehorn P: Extracorporeal immunoadsorption therapy on rats. In vivo depletion of specific antibodies. Clin Exp Immunol 1990; 82:440-444.

    PubMed  CAS  Google Scholar 

  95. Martensson L, Nilsson R, Ohlsson T, Sjogren HO, Strand SE, Tennvall J: Reduced myelotoxicity with sustained tumor concentration of radioimmunoconjugates in rats after extracorporeal depletion. J Nucl Med 2007; 48:269-276.

    PubMed  Google Scholar 

  96. Martensson L, Nilsson R, Sjogren HO, Strand SE, Tennvall J: A nonsurgical technique for blood access in extracorporeal affinity adsorption of antibodies in rats. Artif Organs 2007; 31:312-316.

    PubMed  Google Scholar 

  97. Johansson A, Sandstrom P, Ullen A, Behravan G, Erlandsson A, Levi M, Sundstrom B, Stigbrand T: Epitope specificity of the monoclonal anticytokeratin antibody ts1. Cancer Res 1999; 59:48-51.

    PubMed  CAS  Google Scholar 

  98. Stigbrand T, Andres C, Bellanger L, Bishr Omary M, Bodenmuller H, Bonfrer H, Brundell J, Einarsson R, Erlandsson A, Johansson A, Leca JF, Levi M, Meier T, Nap M, Nustad K, Seguin P, Sjodin A, Sundstrom B, van Dalen A, Wiebelhaus E, Wiklund B, Arlestig L, Hilgers J: Epitope specificity of 30 monoclonal antibodies against cytokeratin antigens: The isobm td5-1 workshop. Tumour Biol 1998; 19:132-152.

    PubMed  CAS  Google Scholar 

  99. Ullen A, Ahlstrom KR, Heitala S, Nilsson B, Arlestig L, Stigbrand T: Secondary antibodies as tools to improve tumor to non tumor ratio at radioimmunolocalisation and radioimmunotherapy. Acta Oncol 1996; 35:281-285.

    PubMed  CAS  Google Scholar 

  100. Ullen A, Nilsson B, Ahlstrom KR, Makiya R, Stigbrand T: In vivo and in vitro interactions between idiotypic and antiidiotypic monoclonal antibodies against placental alkaline phosphatase. J Immunol Methods 1995; 183:155-165.

    PubMed  CAS  Google Scholar 

  101. Ullen A, Riklund Ahlstrom K, Makiya R, Stigbrand T: Syngeneic anti-idiotypic antibodies eliminate excess radiolabeled idiotypes at experimental radioimmunolocalization. Cell Biophys 1995; 27:31-45.

    PubMed  CAS  Google Scholar 

  102. Ullen A, Sandstrom P, Ahlstrom KR, Sundstrom B, Nilsson B, Arlestig L, Stigbrand T: Use of anticytokeratin monoclonal anti-idiotypic antibodies to improve tumor:Nontumor ratio in experimental radioimmunolocalization. Cancer Res 1995; 55:5868s-5873s.

    PubMed  CAS  Google Scholar 

  103. Erlandsson A, Holm P, Ullen A, Stigbrand T, Sundstrom BE: Studies of the interactions between the anticytokeratin 8 monoclonal antibody ts1, its antigen and its anti-idiotypic antibody alphats1. J Mol Recognit 2003; 16:157-163.

    PubMed  CAS  Google Scholar 

  104. Erlandsson A, Eriksson D, Johansson L, Riklund K, Stigbrand T, Sundstrom BE: In vivo clearing of idiotypic antibodies with antiidiotypic antibodies and their derivatives. Mol Immunol 2006; 43:599-606.

    PubMed  CAS  Google Scholar 

  105. Johansson A, Erlandsson A, Eriksson D, Ullen A, Holm P, Sundstrom BE, Roux KH, Stigbrand T: Idiotypic-anti-idiotypic complexes and their in vivo metabolism. Cancer 2002; 94:1306-1313.

    PubMed  CAS  Google Scholar 

  106. Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF: Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 2006; 24:823-834.

    PubMed  CAS  Google Scholar 

  107. Boerman OC, van Schaijk FG, Oyen WJ, Corstens FH: Pretargeted radioimmunotherapy of cancer: Progress step by step. J Nucl Med 2003; 44:400-411.

    PubMed  Google Scholar 

  108. Hnatowich DJ, Virzi F, Rusckowski M: Investigations of avidin and biotin for imaging applications. J Nucl Med 1987; 28:1294-1302.

    PubMed  CAS  Google Scholar 

  109. Axworthy DB, Reno JM, Hylarides MD, Mallett RW, Theodore LJ, Gustavson LM, Su F, Hobson LJ, Beaumier PL, Fritzberg AR: Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci USA 2000; 97:1802-1807.

    PubMed  CAS  Google Scholar 

  110. Zhang M, Zhang Z, Garmestani K, Schultz J, Axworthy DB, Goldman CK, Brechbiel MW, Carrasquillo JA, Waldmann TA: Pretarget radiotherapy with an anti-cd25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc Natl Acad Sci USA 2003; 100:1891-1895.

    PubMed  CAS  Google Scholar 

  111. Sato N, Hassan R, Axworthy DB, Wong KJ, Yu S, Theodore LJ, Lin Y, Park L, Brechbiel MW, Pastan I, Paik CH, Carrasquillo JA: Pretargeted radioimmunotherapy of mesothelinexpressing cancer using a tetravalent single-chain fv-streptavidin fusion protein. J Nucl Med 2005; 46:1201-1209.

    PubMed  Google Scholar 

  112. Cheung NK, Modak S, Lin Y, Guo H, Zanzonico P, Chung J, Zuo Y, Sanderson J, Wilbert S, Theodore LJ, Axworthy DB, Larson SM: Single-chain fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside gd2. J Nucl Med 2004; 45:867-877.

    PubMed  CAS  Google Scholar 

  113. Forero-Torres A, Shen S, Breitz H, Sims RB, Axworthy DB, Khazaeli MB, Chen KH, Percent I, Besh S, LoBuglio AF, Meredith RF: Pretargeted radioimmunotherapy (rit) with a novel anti-tag-72 fusion protein. Cancer Biother Radiopharm 2005; 20:379-390.

    PubMed  CAS  Google Scholar 

  114. Buchsbaum DJ, Khazaeli MB, Axworthy DB, Schultz J, Chaudhuri TR, Zinn KR, Carpenter M, LoBuglio AF: Intraperitoneal pretarget radioimmunotherapy with cc49 fusion protein. Clin Cancer Res 2005; 11:8180-8185.

    PubMed  CAS  Google Scholar 

  115. Paganelli G, Magnani P, Zito F, Villa E, Sudati F, Lopalco L, Rossetti C, Malcovati M, Chiolerio F, Seccamani E, et al.: Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res 1991; 51:5960-5966.

    PubMed  CAS  Google Scholar 

  116. Knox SJ, Goris ML, Tempero M, Weiden PL, Gentner L, Breitz H, Adams GP, Axworthy D, Gaffigan S, Bryan K, Fisher DR, Colcher D, Horak ID, Weiner LM: Phase II trial of yttrium90-dota-biotin pretargeted by nr-lu-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res 2000; 6:406-414.

    PubMed  CAS  Google Scholar 

  117. Breitz HB, Fisher DR, Goris ML, Knox S, Ratliff B, Murtha AD, Weiden PL: Radiation absorbed dose estimation for 90y-dota-biotin with pretargeted nr-lu-10/streptavidin. Cancer Biother Radiopharm 1999; 14:381-395.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Immunology, University of Umeå, SE-90185, Umeå, Sweden

    Torgny Stigbrand & David Eriksson

  2. Department of Diagnostic Radiology, University of Umeå, SE-90185, Umeå, Sweden

    Katrine Riklund

  3. Department of Radiation Physics, University of Umeå, SE-90185, Umeå, Sweden

    Lennart Johansson

Authors
  1. Torgny Stigbrand
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Eriksson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Katrine Riklund
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lennart Johansson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Immunology, University of Umea, Umea, Sweden

    Torgny Stigbrand

  2. Rudbeck Laboratory, Uppsala University, Uppsala, Sweden

    Jörgen Carlsson

  3. Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA

    Gregory P. Adams

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science + Business Media B.V

About this chapter

Cite this chapter

Stigbrand, T., Eriksson, D., Riklund, K., Johansson, L. (2008). Targeting Tumours with Radiolabeled Antibodies. In: Stigbrand, T., Carlsson, J., Adams, G.P. (eds) Targeted Radionuclide Tumor Therapy. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-8696-0_4

Download citation

Publish with us

Policies and ethics

Search

Navigation